TGFB1 and neoplasm: This dual action consequently inhibits multiple key steps in tumor progression, including tumor cell invasiveness, migration, and metastasis.15 Preclinical evidence suggests that neutralization of TGF-β can attenuate the epithelial-to-mesenchymal transition, a process associated with enhanced metastatic potential.16 Moreover, SHR-1701 exhibits the potential to suppress the immunosuppressive TME that is mediated by the TGF-β/TGF-βR signaling pathway.17–19 These mechanisms of action and preclinical findings support further clinical development of SHR-1701.